Agency Information Collection Activities: Proposed Collection; Request, 23029-23030 [2020-08727]

Download as PDF Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than May 11, 2020. A. Federal Reserve Bank of San Francisco (Sebastian Astrada, Director, Applications) 101 Market Street, San Francisco, California 94105–1579: 1. GBank Financial Holdings, Inc., Las Vegas, Nevada; to acquire Bankcard Services LLC, Las Vegas, Nevada, and thereby indirectly engage in data processing activities pursuant to section 225.28(b)(14)(i) of Regulation Y. Board of Governors of the Federal Reserve System, April 21, 2020. Yao-Chin Chao, Assistant Secretary of the Board. [FR Doc. 2020–08783 Filed 4–23–20; 8:45 am] BILLING CODE P [FR Doc. 2020–08782 Filed 4–23–20; 8:45 am] BILLING CODE P GENERAL SERVICES ADMINISTRATION [Notice-MA–2020–06; Docket No. 2020– 0002; Sequence No.15] Relocation Allowances—Waiver of Certain Provisions of the Federal Travel Regulation (FTR) (Chapter 302) for Official Relocation Travel of Employees During the COVID–19 Pandemic Office of Government-wide Policy (OGP), General Services Administration (GSA). ACTION: Notice of GSA Bulletin FTR 20– 06. Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company khammond on DSKJM1Z7X2PROD with NOTICES Board of Governors of the Federal Reserve System, April 21, 2020. Yao-Chin Chao, Assistant Secretary of the Board. AGENCY: FEDERAL RESERVE SYSTEM 17:03 Apr 23, 2020 Jkt 250001 This Federal Travel Regulation (FTR) bulletin informs agencies that certain provisions of the FTR governing official relocation travel are temporarily waived for employees relocating during the national emergency issued by the President on March 13, 2020 concerning the coronavirus disease 2019 (COVID–19). DATES: Applicability Date: This notice is retroactively effective for official relocation travel performed after March 13, 2019, one year prior to the date of the national emergency issued by the President concerning COVID–19. FOR FURTHER INFORMATION CONTACT: For clarification of content, contact Mr. Rodney (Rick) Miller, Senior Program Analyst, Office of Government-wide Policy, Office of Asset and Transportation Management, at 202– 501–3822, or by email at travelpolicy@ gsa.gov. Please cite Notice of FTR Bulletin 20–06. SUPPLEMENTARY INFORMATION: SUMMARY: The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. VerDate Sep<11>2014 Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than May 11, 2020. A. Federal Reserve Bank of Minneapolis (Chris P. Wangen, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. James Sexton, Scottsdale, Arizona; as a member of the Sexton shareholder group to retain voting shares of Kensington Bancorp, Inc., and thereby indirectly retain voting shares of Kensington Bank, both of Kensington, Minnesota. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 23029 Background: Federal agencies authorize relocation entitlements to those individuals listed at FTR § 302– 1.1 and those assigned under the Government Employees Training Act (GETA) (5 U.S.C. Chapter 41). The FTR requires relocating employees to complete all aspects of their relocation within one year or meet an authorized exception. Further, temporary storage of employees’ household goods is limited to 150 days maximum for continental United States (CONUS) to CONUS shipments, and 180 days maximum for shipments with an origin/destination outside the continental United States (OCONUS). Employees are also limited to 10 calendar days to complete a house hunting trip. This FTR bulletin permits agencies to apply GSA-approved waivers to the aforementioned time requirements, within the parameters set forth in the bulletin, to prevent personal hardship to relocating employees impacted by the COVID–19 pandemic. This bulletin can be viewed at https:// www.gsa.gov/ftrbulletins. Jessica Salmoiraghi, Associate Administrator, Office of Government-wide Policy. [FR Doc. 2020–08687 Filed 4–23–20; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Agency Information Collection Activities: Proposed Collection; Request Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (HHS). ACTION: Request for Information; notice of extension of comment period. AGENCY: For the ‘‘Opioid Management in Older Adults’’ project, AHRQ is seeking to identify innovative approaches to managing opioid medications for chronic pain that are particularly relevant for older adults. Use of long-term opioid therapy in older adults can be especially problematic because of increased risks such as delirium, falls, and dementia. Through this notice, the comment period has been extended to June 30, 2020. The subject matter content remains unchanged from the original notice which was previously published on March 18, 2020 (https:// www.govinfo.gov/content/pkg/FR-202003-18/pdf/2020-05612.pdf). SUMMARY: E:\FR\FM\24APN1.SGM 24APN1 23030 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices Information must be received by June 30, 2020. ADDRESSES: Written comments should be submitted by email to: Opioids_ OlderAdults@abtassoc.com. FOR FURTHER INFORMATION CONTACT: Parivash Nourjah, Parivash.nourjah@ ahrq.gov, or 301–427–1106. SUPPLEMENTARY INFORMATION: The United States is in the midst of an unprecedented opioid epidemic that is affecting people from all walks of life. Regulators and policy makers have initiated many activities to curb the epidemic, but relatively little attention has been paid to the growing toll of opioid use, opioid misuse and opioid use disorder (OUD) among older adults. The opioid crisis in older adults is strongly related to challenges in prescription opioid management in this population. Older adults have a high prevalence of chronic pain and are especially vulnerable to suffering adverse events from opioid use, making safe prescribing more challenging even when opioids are an appropriate therapeutic choice. Identifying adverse effects due to opioid use, misuse or abuse is complicated further by factors such as co-occurring medical disorders that can mimic the effects of opioid use. There is also a risk of attributing clinical findings in older adults (e.g. personality changes, falls/balance problems, difficulty sleeping, and heart problems) to other conditions that are also common with age. If adverse events due to opioid prescriptions are identified, finding appropriate alternatives for pain management can be challenging if other pharmacologic options (such as NSAIDS) are contraindicated or mobility issues limit access to other therapeutic options. Diagnosis of substance use disorders is also more complicated in this population. Clinicians may not associate drug misuse or addiction with older adults or they may be inadequately trained in identification and treatment of opioid misuse and OUD among older adults, and hence may not monitor for the signs of opioid use disorder in this population. Successfully optimizing the prescribing and use of opioids in older adults will require addressing the issue khammond on DSKJM1Z7X2PROD with NOTICES DATES: at many points along the care continuum where older adults may need additional attention or a different approach. AHRQ wants to identify specific tools, strategies and approaches to opioid management in older adults throughout the breadth of the care delivery continuum, from avoiding opioid initiation to screening for opioid misuse and opioid use disorder, as well as approaches to opioid tapering in older adults. AHRQ is interested in all innovative approaches that address the opioid management concerns in older adults listed above, but respondents are welcome to address as many or as few as they choose and to address additional areas of interest not listed. Strategies and approaches could come from a variety of health care settings including, but not limited to, primary care and other ambulatory care clinics, emergency departments, home health care organizations, skilled nursing care settings, and inpatient care. Other sources of these strategies might include health care payers, accountable care organizations, and organizations that provide external quality improvement support. Some of the examples of the types of innovations we are looking for might be specific tools or workflows that support providers to assess the risk/ benefit balance of opioids within a multidisciplinary approach in pain management; to optimize and monitor the opioid prescribing when appropriate, including tapering strategies; to screen and treat for opioid misuse or opioid use disorder; or to involve family or other caregivers of an older adult in conversations about opioid safety. Descriptions of strategies or approaches should include the setting where it is deployed and the type of patient population served. This RFI is for planning purposes only and should not be construed as a policy, solicitation for applications, or as an obligation on the part of the Government to provide support for any ideas in response to it. AHRQ will use the information submitted in response to this RFI at its discretion, and will not provide comments to any respondent’s submission. However, responses to the RFI may be reflected in future solicitation(s) or policies. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). The contents of all submissions will be made available to the public upon request. Submitted materials must be publicly available or able to be made public. Dated: April 21, 2020. Virginia L. Mackay-Smith, Associate Director, Office of the Director, AHRQ. [FR Doc. 2020–08727 Filed 4–23–20; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–9124–N] Medicare and Medicaid Programs; Quarterly Listing of Program Issuances—January Through March 2020 Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: This quarterly notice lists CMS manual instructions, substantive and interpretive regulations, and other Federal Register notices that were published from January through March 2020, relating to the Medicare and Medicaid programs and other programs administered by CMS. FOR FURTHER INFORMATION CONTACT: It is possible that an interested party may need specific information and not be able to determine from the listed information whether the issuance or regulation would fulfill that need. Consequently, we are providing contact persons to answer general questions concerning each of the addenda published in this notice. SUMMARY: Addenda Contact I. CMS Manual Instructions .............................................................................................................. II. Regulation Documents Published in the Federal Register ........................................................ III. CMS Rulings ................................................................................................................................ IV. Medicare National Coverage Determinations ............................................................................. V. FDA-Approved Category B IDEs ................................................................................................. VI. Collections of Information ........................................................................................................... VII. Medicare-Approved Carotid Stent Facilities .............................................................................. Ismael Torres ..................... Terri Plumb ......................... Tiffany Lafferty ................... Wanda Belle, MPA ............. John Manlove ..................... William Parham .................. Sarah Fulton, MHS ............ VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\24APN1.SGM 24APN1 Phone No. (410) (410) (410) (410) (410) (410) (410) 786–1864 786–4481 786–7548 786–7491 786–6877 786–4669 786–2749

Agencies

[Federal Register Volume 85, Number 80 (Friday, April 24, 2020)]
[Notices]
[Pages 23029-23030]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08727]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Agency Information Collection Activities: Proposed Collection; 
Request

AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department 
of Health and Human Services (HHS).

ACTION: Request for Information; notice of extension of comment period.

-----------------------------------------------------------------------

SUMMARY: For the ``Opioid Management in Older Adults'' project, AHRQ is 
seeking to identify innovative approaches to managing opioid 
medications for chronic pain that are particularly relevant for older 
adults. Use of long-term opioid therapy in older adults can be 
especially problematic because of increased risks such as delirium, 
falls, and dementia. Through this notice, the comment period has been 
extended to June 30, 2020. The subject matter content remains unchanged 
from the original notice which was previously published on March 18, 
2020 (https://www.govinfo.gov/content/pkg/FR-2020-03-18/pdf/2020-05612.pdf).

[[Page 23030]]


DATES: Information must be received by June 30, 2020.

ADDRESSES: Written comments should be submitted by email to: 
[email protected].

FOR FURTHER INFORMATION CONTACT: Parivash Nourjah, 
[email protected], or 301-427-1106.

SUPPLEMENTARY INFORMATION: 
    The United States is in the midst of an unprecedented opioid 
epidemic that is affecting people from all walks of life. Regulators 
and policy makers have initiated many activities to curb the epidemic, 
but relatively little attention has been paid to the growing toll of 
opioid use, opioid misuse and opioid use disorder (OUD) among older 
adults.
    The opioid crisis in older adults is strongly related to challenges 
in prescription opioid management in this population. Older adults have 
a high prevalence of chronic pain and are especially vulnerable to 
suffering adverse events from opioid use, making safe prescribing more 
challenging even when opioids are an appropriate therapeutic choice. 
Identifying adverse effects due to opioid use, misuse or abuse is 
complicated further by factors such as co-occurring medical disorders 
that can mimic the effects of opioid use. There is also a risk of 
attributing clinical findings in older adults (e.g. personality 
changes, falls/balance problems, difficulty sleeping, and heart 
problems) to other conditions that are also common with age. If adverse 
events due to opioid prescriptions are identified, finding appropriate 
alternatives for pain management can be challenging if other 
pharmacologic options (such as NSAIDS) are contraindicated or mobility 
issues limit access to other therapeutic options.
    Diagnosis of substance use disorders is also more complicated in 
this population. Clinicians may not associate drug misuse or addiction 
with older adults or they may be inadequately trained in identification 
and treatment of opioid misuse and OUD among older adults, and hence 
may not monitor for the signs of opioid use disorder in this 
population.
    Successfully optimizing the prescribing and use of opioids in older 
adults will require addressing the issue at many points along the care 
continuum where older adults may need additional attention or a 
different approach. AHRQ wants to identify specific tools, strategies 
and approaches to opioid management in older adults throughout the 
breadth of the care delivery continuum, from avoiding opioid initiation 
to screening for opioid misuse and opioid use disorder, as well as 
approaches to opioid tapering in older adults.
    AHRQ is interested in all innovative approaches that address the 
opioid management concerns in older adults listed above, but 
respondents are welcome to address as many or as few as they choose and 
to address additional areas of interest not listed.
    Strategies and approaches could come from a variety of health care 
settings including, but not limited to, primary care and other 
ambulatory care clinics, emergency departments, home health care 
organizations, skilled nursing care settings, and inpatient care. Other 
sources of these strategies might include health care payers, 
accountable care organizations, and organizations that provide external 
quality improvement support. Some of the examples of the types of 
innovations we are looking for might be specific tools or workflows 
that support providers to assess the risk/benefit balance of opioids 
within a multidisciplinary approach in pain management; to optimize and 
monitor the opioid prescribing when appropriate, including tapering 
strategies; to screen and treat for opioid misuse or opioid use 
disorder; or to involve family or other caregivers of an older adult in 
conversations about opioid safety. Descriptions of strategies or 
approaches should include the setting where it is deployed and the type 
of patient population served.
    This RFI is for planning purposes only and should not be construed 
as a policy, solicitation for applications, or as an obligation on the 
part of the Government to provide support for any ideas in response to 
it. AHRQ will use the information submitted in response to this RFI at 
its discretion, and will not provide comments to any respondent's 
submission. However, responses to the RFI may be reflected in future 
solicitation(s) or policies. Respondents are advised that the 
Government is under no obligation to acknowledge receipt of the 
information received or provide feedback to respondents with respect to 
any information submitted. No proprietary, classified, confidential or 
sensitive information should be included in your response. The 
Government reserves the right to use any non-proprietary technical 
information in any resultant solicitation(s). The contents of all 
submissions will be made available to the public upon request. 
Submitted materials must be publicly available or able to be made 
public.

    Dated: April 21, 2020.
Virginia L. Mackay-Smith,
Associate Director, Office of the Director, AHRQ.
[FR Doc. 2020-08727 Filed 4-23-20; 8:45 am]
 BILLING CODE 4160-90-P